http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 06 Aug 2026 07:39:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Vanda+Pharmaceuticals+++++For%3A+Jun+30/26878917.html si-local-file:///var/storage/secattach/20260806/26878917.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Vanda+Pharmaceuticals+++++For%3A+Jun+30/26878917.html Thu, 06 Aug 2026 07:39:00 -0400 O.00840259 VNDA http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Vanda+Pharmaceuticals+++++For%3A+Jun+30/26878917.html si-local-file:///var/storage/secattach/20260806/26878917.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Vanda+Pharmaceuticals+++++For%3A+Jun+30/26878917.html Thu, 06 Aug 2026 07:39:00 -0400 O.00840259 VNDA http://www.streetinsider.com/Earnings/Vanda+Pharmaceuticals+%28VNDA%29+Misses+Q2+EPS+by+44c%3B+Offers+Guidance/26873888.html <p>Vanda Pharmaceuticals (NASDAQ: VNDA) reported Q2 EPS of ($1.04), $0.44 worse than the analyst estimate of ($0.60). Revenue for the quarter came in at $50.52 million versus the consensus estimate of $61.78 million.</p><p><strong>GUIDANCE:</strong></p><p>Vanda Pharmaceuticals sees FY2026 revenue of $240-290 million, versus the consensus of $262.1 million.</p><p>For earnings history and earnings-related data on Vanda Pharmaceuticals (VNDA) <a href="http://www.streetinsider.com/ec_earnings.php?q=VNDA">click here</a>.</p> http://www.streetinsider.com/Earnings/Vanda+Pharmaceuticals+%28VNDA%29+Misses+Q2+EPS+by+44c%3B+Offers+Guidance/26873888.html Wed, 05 Aug 2026 16:05:57 -0400 VNDA http://www.streetinsider.com/Guidance/Vanda+Pharmaceuticals+%28VNDA%29+Misses+Q2+EPS+by+44c%3B+Offers+Guidance/26873888.html <p>Vanda Pharmaceuticals (NASDAQ: VNDA) reported Q2 EPS of ($1.04), $0.44 worse than the analyst estimate of ($0.60). Revenue for the quarter came in at $50.52 million versus the consensus estimate of $61.78 million.</p><p><strong>GUIDANCE:</strong></p><p>Vanda Pharmaceuticals sees FY2026 revenue of $240-290 million, versus the consensus of $262.1 million.</p><p>For earnings history and earnings-related data on Vanda Pharmaceuticals (VNDA) <a href="http://www.streetinsider.com/ec_earnings.php?q=VNDA">click here</a>.</p> http://www.streetinsider.com/Guidance/Vanda+Pharmaceuticals+%28VNDA%29+Misses+Q2+EPS+by+44c%3B+Offers+Guidance/26873888.html Wed, 05 Aug 2026 16:05:57 -0400 VNDA http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Vanda+Pharmaceuticals+++++For%3A+Aug+05/26873860.html si-local-file:///var/storage/secattach/20260805/26873860.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Vanda+Pharmaceuticals+++++For%3A+Aug+05/26873860.html Wed, 05 Aug 2026 16:05:00 -0400 O.00840259 VNDA http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Vanda+Pharmaceuticals+++++For%3A+Aug+05/26873860.html si-local-file:///var/storage/secattach/20260805/26873860.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Vanda+Pharmaceuticals+++++For%3A+Aug+05/26873860.html Wed, 05 Aug 2026 16:05:00 -0400 O.00840259 VNDA http://www.streetinsider.com/Press+Releases/Vanda+Pharmaceuticals+Reports+Second+Quarter+2026+Financial+Results/26873597.html <div class="xn-content"> <ul type="disc"><li><i>Fanapt^®Q2 2026 net product sales increased 23% to <money>$36.0 million</money>; total prescriptions increased 31% </i></li><li><i>Full-year 2026 total revenue guidance of <money>$240-$290</money> million </i></li><li><i>Cash totaled <money>$170.0 million</money> as of <chron>June 30, 2026</chron>; expected to fund operations through at least the end of 2027 </i></li><li><i>BYSANTI™ (milsaperidone) received <span value="ACORN:0682203466" idsrc="xmltag.org" >FDA</span> approval for bipolar I disorder and schizophrenia in Q1 2026; commercial launch expected in second half of 2026 </i></li><li><i>Quimilza™ (imsidolimab) BLA for GPP under review by the <span value="ACORN:0682203466" idsrc="xmltag.org" >FDA</span>; PDUFA target action date of December 12, 2026 </i></li><li><i>NEREUS™ for prevention of vomiting induced by motion became commercially available in Q2 2026 </i></li><li><i>Results http://www.streetinsider.com/Press+Releases/Vanda+Pharmaceuticals+Reports+Second+Quarter+2026+Financial+Results/26873597.html Wed, 05 Aug 2026 16:01:00 -0400 A.05963196 A.06822034 A.31066700 O.00840259 O.05375760 O.20026344 O.22422661 VNDA http://www.streetinsider.com/Press+Releases/Vanda+Pharmaceuticals+Reports+Second+Quarter+2026+Financial+Results/26873597.html <div class="xn-content"> <ul type="disc"><li><i>Fanapt^®Q2 2026 net product sales increased 23% to <money>$36.0 million</money>; total prescriptions increased 31% </i></li><li><i>Full-year 2026 total revenue guidance of <money>$240-$290</money> million </i></li><li><i>Cash totaled <money>$170.0 million</money> as of <chron>June 30, 2026</chron>; expected to fund operations through at least the end of 2027 </i></li><li><i>BYSANTI™ (milsaperidone) received <span value="ACORN:0682203466" idsrc="xmltag.org" >FDA</span> approval for bipolar I disorder and schizophrenia in Q1 2026; commercial launch expected in second half of 2026 </i></li><li><i>Quimilza™ (imsidolimab) BLA for GPP under review by the <span value="ACORN:0682203466" idsrc="xmltag.org" >FDA</span>; PDUFA target action date of December 12, 2026 </i></li><li><i>NEREUS™ for prevention of vomiting induced by motion became commercially available in Q2 2026 </i></li><li><i>Results http://www.streetinsider.com/Press+Releases/Vanda+Pharmaceuticals+Reports+Second+Quarter+2026+Financial+Results/26873597.html Wed, 05 Aug 2026 16:01:00 -0400 A.05963196 A.06822034 A.31066700 O.00840259 O.05375760 O.20026344 O.22422661 VNDA http://www.streetinsider.com/Press+Releases/Vanda+Pharmaceuticals+Reports+Second+Quarter+2026+Financial+Results/26873597.html <div class="xn-content"> <ul type="disc"><li><i>Fanapt^®Q2 2026 net product sales increased 23% to <money>$36.0 million</money>; total prescriptions increased 31% </i></li><li><i>Full-year 2026 total revenue guidance of <money>$240-$290</money> million </i></li><li><i>Cash totaled <money>$170.0 million</money> as of <chron>June 30, 2026</chron>; expected to fund operations through at least the end of 2027 </i></li><li><i>BYSANTI™ (milsaperidone) received <span value="ACORN:0682203466" idsrc="xmltag.org" >FDA</span> approval for bipolar I disorder and schizophrenia in Q1 2026; commercial launch expected in second half of 2026 </i></li><li><i>Quimilza™ (imsidolimab) BLA for GPP under review by the <span value="ACORN:0682203466" idsrc="xmltag.org" >FDA</span>; PDUFA target action date of December 12, 2026 </i></li><li><i>NEREUS™ for prevention of vomiting induced by motion became commercially available in Q2 2026 </i></li><li><i>Results http://www.streetinsider.com/Press+Releases/Vanda+Pharmaceuticals+Reports+Second+Quarter+2026+Financial+Results/26873597.html Wed, 05 Aug 2026 16:01:00 -0400 A.05963196 A.06822034 A.31066700 O.00840259 O.05375760 O.20026344 O.22422661 VNDA http://www.streetinsider.com/Press+Releases/Vanda+Pharmaceuticals+Reports+Second+Quarter+2026+Financial+Results/26873597.html <div class="xn-content"> <ul type="disc"><li><i>Fanapt^®Q2 2026 net product sales increased 23% to <money>$36.0 million</money>; total prescriptions increased 31% </i></li><li><i>Full-year 2026 total revenue guidance of <money>$240-$290</money> million </i></li><li><i>Cash totaled <money>$170.0 million</money> as of <chron>June 30, 2026</chron>; expected to fund operations through at least the end of 2027 </i></li><li><i>BYSANTI™ (milsaperidone) received <span value="ACORN:0682203466" idsrc="xmltag.org" >FDA</span> approval for bipolar I disorder and schizophrenia in Q1 2026; commercial launch expected in second half of 2026 </i></li><li><i>Quimilza™ (imsidolimab) BLA for GPP under review by the <span value="ACORN:0682203466" idsrc="xmltag.org" >FDA</span>; PDUFA target action date of December 12, 2026 </i></li><li><i>NEREUS™ for prevention of vomiting induced by motion became commercially available in Q2 2026 </i></li><li><i>Results http://www.streetinsider.com/Press+Releases/Vanda+Pharmaceuticals+Reports+Second+Quarter+2026+Financial+Results/26873597.html Wed, 05 Aug 2026 16:01:00 -0400 A.05963196 A.06822034 A.31066700 O.00840259 O.05375760 O.20026344 O.22422661 VNDA http://www.streetinsider.com/Press+Releases/Vanda+Pharmaceuticals+Reports+Second+Quarter+2026+Financial+Results/26873597.html <div class="xn-content"> <ul type="disc"><li><i>Fanapt^®Q2 2026 net product sales increased 23% to <money>$36.0 million</money>; total prescriptions increased 31% </i></li><li><i>Full-year 2026 total revenue guidance of <money>$240-$290</money> million </i></li><li><i>Cash totaled <money>$170.0 million</money> as of <chron>June 30, 2026</chron>; expected to fund operations through at least the end of 2027 </i></li><li><i>BYSANTI™ (milsaperidone) received <span value="ACORN:0682203466" idsrc="xmltag.org" >FDA</span> approval for bipolar I disorder and schizophrenia in Q1 2026; commercial launch expected in second half of 2026 </i></li><li><i>Quimilza™ (imsidolimab) BLA for GPP under review by the <span value="ACORN:0682203466" idsrc="xmltag.org" >FDA</span>; PDUFA target action date of December 12, 2026 </i></li><li><i>NEREUS™ for prevention of vomiting induced by motion became commercially available in Q2 2026 </i></li><li><i>Results http://www.streetinsider.com/Press+Releases/Vanda+Pharmaceuticals+Reports+Second+Quarter+2026+Financial+Results/26873597.html Wed, 05 Aug 2026 16:01:00 -0400 A.05963196 A.06822034 A.31066700 O.00840259 O.05375760 O.20026344 O.22422661 VNDA http://www.streetinsider.com/Press+Releases/Vanda+Pharmaceuticals+Reports+Second+Quarter+2026+Financial+Results/26873597.html <div class="xn-content"> <ul type="disc"><li><i>Fanapt^®Q2 2026 net product sales increased 23% to <money>$36.0 million</money>; total prescriptions increased 31% </i></li><li><i>Full-year 2026 total revenue guidance of <money>$240-$290</money> million </i></li><li><i>Cash totaled <money>$170.0 million</money> as of <chron>June 30, 2026</chron>; expected to fund operations through at least the end of 2027 </i></li><li><i>BYSANTI™ (milsaperidone) received <span value="ACORN:0682203466" idsrc="xmltag.org" >FDA</span> approval for bipolar I disorder and schizophrenia in Q1 2026; commercial launch expected in second half of 2026 </i></li><li><i>Quimilza™ (imsidolimab) BLA for GPP under review by the <span value="ACORN:0682203466" idsrc="xmltag.org" >FDA</span>; PDUFA target action date of December 12, 2026 </i></li><li><i>NEREUS™ for prevention of vomiting induced by motion became commercially available in Q2 2026 </i></li><li><i>Results http://www.streetinsider.com/Press+Releases/Vanda+Pharmaceuticals+Reports+Second+Quarter+2026+Financial+Results/26873597.html Wed, 05 Aug 2026 16:01:00 -0400 A.05963196 A.06822034 A.31066700 O.00840259 O.05375760 O.20026344 O.22422661 VNDA http://www.streetinsider.com/Press+Releases/Vanda+Pharmaceuticals+Reports+Second+Quarter+2026+Financial+Results/26873597.html <div class="xn-content"> <ul type="disc"><li><i>Fanapt^®Q2 2026 net product sales increased 23% to <money>$36.0 million</money>; total prescriptions increased 31% </i></li><li><i>Full-year 2026 total revenue guidance of <money>$240-$290</money> million </i></li><li><i>Cash totaled <money>$170.0 million</money> as of <chron>June 30, 2026</chron>; expected to fund operations through at least the end of 2027 </i></li><li><i>BYSANTI™ (milsaperidone) received <span value="ACORN:0682203466" idsrc="xmltag.org" >FDA</span> approval for bipolar I disorder and schizophrenia in Q1 2026; commercial launch expected in second half of 2026 </i></li><li><i>Quimilza™ (imsidolimab) BLA for GPP under review by the <span value="ACORN:0682203466" idsrc="xmltag.org" >FDA</span>; PDUFA target action date of December 12, 2026 </i></li><li><i>NEREUS™ for prevention of vomiting induced by motion became commercially available in Q2 2026 </i></li><li><i>Results http://www.streetinsider.com/Press+Releases/Vanda+Pharmaceuticals+Reports+Second+Quarter+2026+Financial+Results/26873597.html Wed, 05 Aug 2026 16:01:00 -0400 A.05963196 A.06822034 A.31066700 O.00840259 O.05375760 O.20026344 O.22422661 VNDA http://www.streetinsider.com/Press+Releases/Vanda+Pharmaceuticals+Reports+Second+Quarter+2026+Financial+Results/26873597.html <div class="xn-content"> <ul type="disc"><li><i>Fanapt^®Q2 2026 net product sales increased 23% to <money>$36.0 million</money>; total prescriptions increased 31% </i></li><li><i>Full-year 2026 total revenue guidance of <money>$240-$290</money> million </i></li><li><i>Cash totaled <money>$170.0 million</money> as of <chron>June 30, 2026</chron>; expected to fund operations through at least the end of 2027 </i></li><li><i>BYSANTI™ (milsaperidone) received <span value="ACORN:0682203466" idsrc="xmltag.org" >FDA</span> approval for bipolar I disorder and schizophrenia in Q1 2026; commercial launch expected in second half of 2026 </i></li><li><i>Quimilza™ (imsidolimab) BLA for GPP under review by the <span value="ACORN:0682203466" idsrc="xmltag.org" >FDA</span>; PDUFA target action date of December 12, 2026 </i></li><li><i>NEREUS™ for prevention of vomiting induced by motion became commercially available in Q2 2026 </i></li><li><i>Results http://www.streetinsider.com/Press+Releases/Vanda+Pharmaceuticals+Reports+Second+Quarter+2026+Financial+Results/26873597.html Wed, 05 Aug 2026 16:01:00 -0400 A.05963196 A.06822034 A.31066700 O.00840259 O.05375760 O.20026344 O.22422661 VNDA http://www.streetinsider.com/PRNewswire/Vanda+Pharmaceuticals+Reports+Second+Quarter+2026+Financial+Results/26873597.html <div class="xn-content"> <ul type="disc"><li><i>Fanapt^®Q2 2026 net product sales increased 23% to <money>$36.0 million</money>; total prescriptions increased 31% </i></li><li><i>Full-year 2026 total revenue guidance of <money>$240-$290</money> million </i></li><li><i>Cash totaled <money>$170.0 million</money> as of <chron>June 30, 2026</chron>; expected to fund operations through at least the end of 2027 </i></li><li><i>BYSANTI™ (milsaperidone) received <span value="ACORN:0682203466" idsrc="xmltag.org" >FDA</span> approval for bipolar I disorder and schizophrenia in Q1 2026; commercial launch expected in second half of 2026 </i></li><li><i>Quimilza™ (imsidolimab) BLA for GPP under review by the <span value="ACORN:0682203466" idsrc="xmltag.org" >FDA</span>; PDUFA target action date of December 12, 2026 </i></li><li><i>NEREUS™ for prevention of vomiting induced by motion became commercially available in Q2 2026 </i></li><li><i>Results http://www.streetinsider.com/PRNewswire/Vanda+Pharmaceuticals+Reports+Second+Quarter+2026+Financial+Results/26873597.html Wed, 05 Aug 2026 16:01:00 -0400 A.05963196 A.06822034 A.31066700 O.00840259 O.05375760 O.20026344 O.22422661 VNDA http://www.streetinsider.com/PRNewswire/Vanda+Pharmaceuticals+Reports+Second+Quarter+2026+Financial+Results/26873597.html <div class="xn-content"> <ul type="disc"><li><i>Fanapt^®Q2 2026 net product sales increased 23% to <money>$36.0 million</money>; total prescriptions increased 31% </i></li><li><i>Full-year 2026 total revenue guidance of <money>$240-$290</money> million </i></li><li><i>Cash totaled <money>$170.0 million</money> as of <chron>June 30, 2026</chron>; expected to fund operations through at least the end of 2027 </i></li><li><i>BYSANTI™ (milsaperidone) received <span value="ACORN:0682203466" idsrc="xmltag.org" >FDA</span> approval for bipolar I disorder and schizophrenia in Q1 2026; commercial launch expected in second half of 2026 </i></li><li><i>Quimilza™ (imsidolimab) BLA for GPP under review by the <span value="ACORN:0682203466" idsrc="xmltag.org" >FDA</span>; PDUFA target action date of December 12, 2026 </i></li><li><i>NEREUS™ for prevention of vomiting induced by motion became commercially available in Q2 2026 </i></li><li><i>Results http://www.streetinsider.com/PRNewswire/Vanda+Pharmaceuticals+Reports+Second+Quarter+2026+Financial+Results/26873597.html Wed, 05 Aug 2026 16:01:00 -0400 A.05963196 A.06822034 A.31066700 O.00840259 O.05375760 O.20026344 O.22422661 VNDA http://www.streetinsider.com/PRNewswire/Vanda+Pharmaceuticals+Reports+Second+Quarter+2026+Financial+Results/26873597.html <div class="xn-content"> <ul type="disc"><li><i>Fanapt^®Q2 2026 net product sales increased 23% to <money>$36.0 million</money>; total prescriptions increased 31% </i></li><li><i>Full-year 2026 total revenue guidance of <money>$240-$290</money> million </i></li><li><i>Cash totaled <money>$170.0 million</money> as of <chron>June 30, 2026</chron>; expected to fund operations through at least the end of 2027 </i></li><li><i>BYSANTI™ (milsaperidone) received <span value="ACORN:0682203466" idsrc="xmltag.org" >FDA</span> approval for bipolar I disorder and schizophrenia in Q1 2026; commercial launch expected in second half of 2026 </i></li><li><i>Quimilza™ (imsidolimab) BLA for GPP under review by the <span value="ACORN:0682203466" idsrc="xmltag.org" >FDA</span>; PDUFA target action date of December 12, 2026 </i></li><li><i>NEREUS™ for prevention of vomiting induced by motion became commercially available in Q2 2026 </i></li><li><i>Results http://www.streetinsider.com/PRNewswire/Vanda+Pharmaceuticals+Reports+Second+Quarter+2026+Financial+Results/26873597.html Wed, 05 Aug 2026 16:01:00 -0400 A.05963196 A.06822034 A.31066700 O.00840259 O.05375760 O.20026344 O.22422661 VNDA http://www.streetinsider.com/PRNewswire/Vanda+Pharmaceuticals+Reports+Second+Quarter+2026+Financial+Results/26873597.html <div class="xn-content"> <ul type="disc"><li><i>Fanapt^®Q2 2026 net product sales increased 23% to <money>$36.0 million</money>; total prescriptions increased 31% </i></li><li><i>Full-year 2026 total revenue guidance of <money>$240-$290</money> million </i></li><li><i>Cash totaled <money>$170.0 million</money> as of <chron>June 30, 2026</chron>; expected to fund operations through at least the end of 2027 </i></li><li><i>BYSANTI™ (milsaperidone) received <span value="ACORN:0682203466" idsrc="xmltag.org" >FDA</span> approval for bipolar I disorder and schizophrenia in Q1 2026; commercial launch expected in second half of 2026 </i></li><li><i>Quimilza™ (imsidolimab) BLA for GPP under review by the <span value="ACORN:0682203466" idsrc="xmltag.org" >FDA</span>; PDUFA target action date of December 12, 2026 </i></li><li><i>NEREUS™ for prevention of vomiting induced by motion became commercially available in Q2 2026 </i></li><li><i>Results http://www.streetinsider.com/PRNewswire/Vanda+Pharmaceuticals+Reports+Second+Quarter+2026+Financial+Results/26873597.html Wed, 05 Aug 2026 16:01:00 -0400 A.05963196 A.06822034 A.31066700 O.00840259 O.05375760 O.20026344 O.22422661 VNDA http://www.streetinsider.com/PRNewswire/Vanda+Pharmaceuticals+Reports+Second+Quarter+2026+Financial+Results/26873597.html <div class="xn-content"> <ul type="disc"><li><i>Fanapt^®Q2 2026 net product sales increased 23% to <money>$36.0 million</money>; total prescriptions increased 31% </i></li><li><i>Full-year 2026 total revenue guidance of <money>$240-$290</money> million </i></li><li><i>Cash totaled <money>$170.0 million</money> as of <chron>June 30, 2026</chron>; expected to fund operations through at least the end of 2027 </i></li><li><i>BYSANTI™ (milsaperidone) received <span value="ACORN:0682203466" idsrc="xmltag.org" >FDA</span> approval for bipolar I disorder and schizophrenia in Q1 2026; commercial launch expected in second half of 2026 </i></li><li><i>Quimilza™ (imsidolimab) BLA for GPP under review by the <span value="ACORN:0682203466" idsrc="xmltag.org" >FDA</span>; PDUFA target action date of December 12, 2026 </i></li><li><i>NEREUS™ for prevention of vomiting induced by motion became commercially available in Q2 2026 </i></li><li><i>Results http://www.streetinsider.com/PRNewswire/Vanda+Pharmaceuticals+Reports+Second+Quarter+2026+Financial+Results/26873597.html Wed, 05 Aug 2026 16:01:00 -0400 A.05963196 A.06822034 A.31066700 O.00840259 O.05375760 O.20026344 O.22422661 VNDA http://www.streetinsider.com/PRNewswire/Vanda+Pharmaceuticals+Reports+Second+Quarter+2026+Financial+Results/26873597.html <div class="xn-content"> <ul type="disc"><li><i>Fanapt^®Q2 2026 net product sales increased 23% to <money>$36.0 million</money>; total prescriptions increased 31% </i></li><li><i>Full-year 2026 total revenue guidance of <money>$240-$290</money> million </i></li><li><i>Cash totaled <money>$170.0 million</money> as of <chron>June 30, 2026</chron>; expected to fund operations through at least the end of 2027 </i></li><li><i>BYSANTI™ (milsaperidone) received <span value="ACORN:0682203466" idsrc="xmltag.org" >FDA</span> approval for bipolar I disorder and schizophrenia in Q1 2026; commercial launch expected in second half of 2026 </i></li><li><i>Quimilza™ (imsidolimab) BLA for GPP under review by the <span value="ACORN:0682203466" idsrc="xmltag.org" >FDA</span>; PDUFA target action date of December 12, 2026 </i></li><li><i>NEREUS™ for prevention of vomiting induced by motion became commercially available in Q2 2026 </i></li><li><i>Results http://www.streetinsider.com/PRNewswire/Vanda+Pharmaceuticals+Reports+Second+Quarter+2026+Financial+Results/26873597.html Wed, 05 Aug 2026 16:01:00 -0400 A.05963196 A.06822034 A.31066700 O.00840259 O.05375760 O.20026344 O.22422661 VNDA http://www.streetinsider.com/PRNewswire/Vanda+Pharmaceuticals+Reports+Second+Quarter+2026+Financial+Results/26873597.html <div class="xn-content"> <ul type="disc"><li><i>Fanapt^®Q2 2026 net product sales increased 23% to <money>$36.0 million</money>; total prescriptions increased 31% </i></li><li><i>Full-year 2026 total revenue guidance of <money>$240-$290</money> million </i></li><li><i>Cash totaled <money>$170.0 million</money> as of <chron>June 30, 2026</chron>; expected to fund operations through at least the end of 2027 </i></li><li><i>BYSANTI™ (milsaperidone) received <span value="ACORN:0682203466" idsrc="xmltag.org" >FDA</span> approval for bipolar I disorder and schizophrenia in Q1 2026; commercial launch expected in second half of 2026 </i></li><li><i>Quimilza™ (imsidolimab) BLA for GPP under review by the <span value="ACORN:0682203466" idsrc="xmltag.org" >FDA</span>; PDUFA target action date of December 12, 2026 </i></li><li><i>NEREUS™ for prevention of vomiting induced by motion became commercially available in Q2 2026 </i></li><li><i>Results http://www.streetinsider.com/PRNewswire/Vanda+Pharmaceuticals+Reports+Second+Quarter+2026+Financial+Results/26873597.html Wed, 05 Aug 2026 16:01:00 -0400 A.05963196 A.06822034 A.31066700 O.00840259 O.05375760 O.20026344 O.22422661 VNDA http://www.streetinsider.com/PRNewswire/Vanda+Pharmaceuticals+Reports+Second+Quarter+2026+Financial+Results/26873597.html <div class="xn-content"> <ul type="disc"><li><i>Fanapt^®Q2 2026 net product sales increased 23% to <money>$36.0 million</money>; total prescriptions increased 31% </i></li><li><i>Full-year 2026 total revenue guidance of <money>$240-$290</money> million </i></li><li><i>Cash totaled <money>$170.0 million</money> as of <chron>June 30, 2026</chron>; expected to fund operations through at least the end of 2027 </i></li><li><i>BYSANTI™ (milsaperidone) received <span value="ACORN:0682203466" idsrc="xmltag.org" >FDA</span> approval for bipolar I disorder and schizophrenia in Q1 2026; commercial launch expected in second half of 2026 </i></li><li><i>Quimilza™ (imsidolimab) BLA for GPP under review by the <span value="ACORN:0682203466" idsrc="xmltag.org" >FDA</span>; PDUFA target action date of December 12, 2026 </i></li><li><i>NEREUS™ for prevention of vomiting induced by motion became commercially available in Q2 2026 </i></li><li><i>Results http://www.streetinsider.com/PRNewswire/Vanda+Pharmaceuticals+Reports+Second+Quarter+2026+Financial+Results/26873597.html Wed, 05 Aug 2026 16:01:00 -0400 A.05963196 A.06822034 A.31066700 O.00840259 O.05375760 O.20026344 O.22422661 VNDA http://www.streetinsider.com/Press+Releases/Vanda+Pharmaceuticals+to+Announce+Second+Quarter+2026+Financial+Results+on+August+5%2C+2026/26835746.html <div class="xn-content"> <p class="prntac"><b>Conference Call and Webcast to Follow</b></p><p><span class="legendSpanClass"><location value="LU/us.dc.wash" idsrc="xmltag.org" >WASHINGTON</location></span>, <span class="legendSpanClass"><chron>July 29, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:VNDA" idsrc="xmltag.org" >Vanda Pharmaceuticals Inc.</span> (Vanda) (Nasdaq: VNDA) today announced it will release results for the second quarter 2026 on <chron>Wednesday, August 5, 2026</chron>, after the market closes.  </p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> <img src="https://mmx.prnewswire.com/media/MS637926/VandaLogo-v1.jpg?id=OA2800551" title="Vanda Logo" alt="Vanda Logo" /> http://www.streetinsider.com/Press+Releases/Vanda+Pharmaceuticals+to+Announce+Second+Quarter+2026+Financial+Results+on+August+5%2C+2026/26835746.html Wed, 29 Jul 2026 16:31:00 -0400 O.00840259 VNDA http://www.streetinsider.com/Press+Releases/Vanda+Pharmaceuticals+to+Announce+Second+Quarter+2026+Financial+Results+on+August+5%2C+2026/26835746.html <div class="xn-content"> <p class="prntac"><b>Conference Call and Webcast to Follow</b></p><p><span class="legendSpanClass"><location value="LU/us.dc.wash" idsrc="xmltag.org" >WASHINGTON</location></span>, <span class="legendSpanClass"><chron>July 29, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:VNDA" idsrc="xmltag.org" >Vanda Pharmaceuticals Inc.</span> (Vanda) (Nasdaq: VNDA) today announced it will release results for the second quarter 2026 on <chron>Wednesday, August 5, 2026</chron>, after the market closes.  </p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> <img src="https://mmx.prnewswire.com/media/MS637926/VandaLogo-v1.jpg?id=OA2800551" title="Vanda Logo" alt="Vanda Logo" /> http://www.streetinsider.com/Press+Releases/Vanda+Pharmaceuticals+to+Announce+Second+Quarter+2026+Financial+Results+on+August+5%2C+2026/26835746.html Wed, 29 Jul 2026 16:31:00 -0400 O.00840259 VNDA http://www.streetinsider.com/PRNewswire/Vanda+Pharmaceuticals+to+Announce+Second+Quarter+2026+Financial+Results+on+August+5%2C+2026/26835746.html <div class="xn-content"> <p class="prntac"><b>Conference Call and Webcast to Follow</b></p><p><span class="legendSpanClass"><location value="LU/us.dc.wash" idsrc="xmltag.org" >WASHINGTON</location></span>, <span class="legendSpanClass"><chron>July 29, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:VNDA" idsrc="xmltag.org" >Vanda Pharmaceuticals Inc.</span> (Vanda) (Nasdaq: VNDA) today announced it will release results for the second quarter 2026 on <chron>Wednesday, August 5, 2026</chron>, after the market closes.  </p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> <img src="https://mmx.prnewswire.com/media/MS637926/VandaLogo-v1.jpg?id=OA2800551" title="Vanda Logo" alt="Vanda Logo" /> http://www.streetinsider.com/PRNewswire/Vanda+Pharmaceuticals+to+Announce+Second+Quarter+2026+Financial+Results+on+August+5%2C+2026/26835746.html Wed, 29 Jul 2026 16:31:00 -0400 O.00840259 VNDA